|
Volumn 46, Issue 3, 2000, Pages 173-179
|
Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma
|
Author keywords
Angiogenesis; Kaposi's sarcoma; Mass spectrometry; Metabolism; Pharmacokinetics; TNP 470
|
Indexed keywords
FUMAGILLOL CHLOROACETYLCARBAMATE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ADULT;
ANGIOGENESIS;
AREA UNDER THE CURVE;
ARTICLE;
CELL PROLIFERATION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COHORT ANALYSIS;
DOSE CALCULATION;
DRUG HALF LIFE;
ENDOTHELIUM CELL;
FEMALE;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
KAPOSI SARCOMA;
MALE;
PHASE 1 CLINICAL TRIAL;
PLASMA CLEARANCE;
PRIORITY JOURNAL;
ACQUIRED IMMUNODEFICIENCY SYNDROME;
ANGIOGENESIS INHIBITORS;
ANTIBIOTICS, ANTINEOPLASTIC;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
CYCLOHEXANES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HUMANS;
INFUSIONS, INTRAVENOUS;
MASS SPECTROMETRY;
SARCOMA, KAPOSI;
SENSITIVITY AND SPECIFICITY;
SESQUITERPENES;
|
EID: 0033797806
PISSN: 03445704
EISSN: None
Source Type: Journal
DOI: 10.1007/s002800000149 Document Type: Article |
Times cited : (22)
|
References (26)
|